Business Wire

The Machine Industry Wants Even More 3D Control, so Unicontrol Now Has a Solution for Wheel Loaders

15.9.2021 09:00:00 EEST | Business Wire | Press release

Share

Yet another demand is met for the construction industry, with precise and efficient excavation work. Unicontrol now has a solution ready that makes it much easier to carry out grading using a loader. Machine operators can now level and set surfaces precisely using the loader via drawings and GPS, without any assistance from a manual worker and a surveyor. The Unicontrol 3D machine control system is now available for excavators and wheel loaders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914006043/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The machine industry wants even more 3D control, so Unicontrol now has a solution for wheel loaders (Photo: Business Wire)

The shortage of skilled labour in the construction industry is a growing problem. Contractors are constantly looking for machine operators. Unicontrol meets this challenge using technology that ensures better utilisation of resources on construction sites, by making the individual machine operator more independent and productive.

Unicontrol’s new 3D solution can be installed on all types of wheel loaders. Unicontrol is the first company in the world that now supports articulated body sensors and installs antennas on the roof.

Better machine utilisation

3D machine control for loaders was developed in collaboration with Unicontrol’s distributors.

“The construction industry wants to use wheel loaders for even more tasks than moving equipment and loading lorries. Using 3D machine control, the contractor can also use a loader for several tasks, including when surfaces need to be levelled and set. And if the grading has meant that a manhole cover has become hidden, Unicontrol’s solution can quickly localise it without having to call in a surveyor. Overall, Unicontrol’s technology increases machine utilisation and productivity on the site,” stated Johan Spector, partner at distributor L5 Navigation.

With Unicontrol3D fitted on the machine, fast-tracking is ensured, so the system can always follow the machine, and the machine operator can carry out the work precisely.

“There is a clear need for a simple 3D machine control system that has a short training time and is sold at an affordable price,” said Ehsan Ekhlas, CCO at Unicontrol.

At construction company Gorm Hansen in Denmark, Technical Manager Henrik Vestergaard is very satisfied with the new technological possibilities: “Unicontrol3D is an excellent tool for ensuring precise grading, no matter the level of experience the machine operator has. We reach our goals much faster now when it comes to levelling tasks.”

Unicontrol was established in 2018 and now sells its technology in more than 15 countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Malene Grouleff
Grouleff communications ApS
Malene@grouleff.it

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye